

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

\* \* \* \* \* RECONNECTED TO STN INTERNATIONAL \* \* \* \* \*  
SESSION RESUMED IN FILE 'REGISTRY' AT 19:14:00 ON 13 MAR 2008  
FILE 'REGISTRY' ENTERED AT 19:14:00 ON 13 MAR 2008  
COPYRIGHT (C) 2008 American Chemical Society (ACS)  
COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.46	0.67

=> file reg

COST IN U.S. DOLLARS

	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.46	0.67

FILE 'REGISTRY' ENTERED AT 19:14:16 ON 13 MAR 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
provided by InfoChem.

STRUCTURE FILE UPDATES: 12 MAR 2008 HIGHEST RN 1007632-31-6  
DICTIONARY FILE UPDATES: 12 MAR 2008 HIGHEST RN 1007632-31-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
predicted properties as well as tags indicating availability of  
experimental property data in the original document. For information  
on property searching in REGISTRY, refer to:


<http://www.cas.org/support/stngen/stdoc/properties.html>

=> s creatine/cn

L1 1 CREATINE/CN

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 57-00-1 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Creatine (8CI)  
 OTHER NAMES:  
 CN Cosmocair C 100  
 CN Methylguanidoacetic acid  
 CN N-Methyl-N-guanylglycine  
 CN Neotine  
 CN NSC 8752  
 CN Phosphagen  
 CN Tego Cosmo C 100  
 MF C4 H9 N3 O2  
 CI COM  
 LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS,  
 BIOTECHNO, CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST,  
 CIN, CSCHEM, CSNB, DDFU, DETHERM\*, DRUGU, EMBASE, GMELIN\*, HSDB\*,  
 IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, PIRA,  
 PROMT, SPECINFO, TOXCENTER, USPAT2, USPATFULL, USPATOLD  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)




\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7024 REFERENCES IN FILE CA (1907 TO DATE)  
 151 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 7045 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 3 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

```
=> s creatine phosphate/cn
L2          1 CREATINE PHOSPHATE/CN

=> d 12
```

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
 RN 67-07-2 REGISTRY  
 ED Entered STN: 16 Nov 1984  
 CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (CA INDEX NAME)  
 OTHER CA INDEX NAMES:  
 CN Sarcosine, N-(phosphonoamidino)- (8CI)  
 OTHER NAMES:  
 CN Creatine phosphate  
 CN Creatinephosphoric acid  
 CN N-(Phosphonoamidino)sarcosine  
 CN N-Phosphocreatine  
 CN N-Phosphorylcreatine  
 CN Phosphocreatine  
 CN Phosphorylcreatine  
 MF C4 H10 N3 O5 P  
 CI COM  
 LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOSIS, BIOTECHNO,  
 CA, CABA, CAOLD, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN,  
 CSCHEM, DDFU, DRUGU, EMBASE, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,  
 MRCK\*, PROMT, PROUSDDR, TOXCENTER, USPAT2, USPATFULL, USPATOLD  
 (\*File contains numerically searchable property data)  
 Other Sources: DSL\*\*, EINECS\*\*, TSCA\*\*  
 (\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

7530 REFERENCES IN FILE CA (1907 TO DATE)  
 30 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 7540 REFERENCES IN FILE CAPLUS (1907 TO DATE)  
 35 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

=> file caplus		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	14.76	15.43

FILE 'CAPLUS' ENTERED AT 19:15:07 ON 13 MAR 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 13 Mar 2008 VOL 148 ISS 11  
 FILE LAST UPDATED: 12 Mar 2008 (20080312/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l1 full  
 L3 7045 L1

=> s l2 full  
 L4 7540 L2

=> s (l3 or l4) and (glutamate excitotoxicity or benoquinone or nicotinamide or spin traps or growth factor or aspirin or nitric oxide synthase or cyclooxygenase 2 or ICE or neuroimmunophilis or acetylcysteine or antioxidants or lipoic acid or cofactors or riboflavin or CoQ10)

112116 GLUTAMATE  
 1141 GLUTAMATES  
 112534 GLUTAMATE  
 (GLUTAMATE OR GLUTAMATES)  
 12 EXCITOTOXITY  
 2 GLUTAMATE EXCITOTOXITY  
 (GLUTAMATE(W)EXCITOTOXITY)  
 3 BENOQUINONE  
 23096 NICOTINAMIDE  
 427 NICOTINAMIDES  
 23211 NICOTINAMIDE  
 (NICOTINAMIDE OR NICOTINAMIDES)  
 425310 SPIN  
 30171 SPINS  
 434591 SPIN  
 (SPIN OR SPINS)  
 58016 TRAPS  
 846 SPIN TRAPS  
 (SPIN(W)TRAPS)  
 1420281 GROWTH  
 4638 GROWTHS  
 1422622 GROWTH  
 (GROWTH OR GROWTHS)

1107589 FACTOR  
 1004623 FACTORS  
 1745099 FACTOR  
     (FACTOR OR FACTORS)  
 217435 GROWTH FACTOR  
     (GROWTH(W)FACTOR)  
     21 ASPRIN  
 199098 NITRIC  
     3 NITRICS  
 199101 NITRIC  
     (NITRIC OR NITRICS)  
 1845831 OXIDE  
 356853 OXIDES  
 1946491 OXIDE  
     (OXIDE OR OXIDES)  
 111930 SYNTHASE  
     6391 SYNTHASES  
 113117 SYNTHASE  
     (SYNTHASE OR SYNTHASES)  
 37350 NITRIC OXIDE SYNTHASE  
     (NITRIC(W)OXIDE(W)SYNTHASE)  
 29948 CYCLOOXYGENASE  
     1047 CYCLOOXYGENASES  
     30197 CYCLOOXYGENASE  
         (CYCLOOXYGENASE OR CYCLOOXYGENASES)  
 9517007 2  
     13696 CYCLOOXYGENASE 2  
         (CYCLOOXYGENASE(W)2)  
 117790 ICE  
     2120 ICES  
 118347 ICE  
     (ICE OR ICES)  
     0 NEUROIMMUNOPHILIS  
     7437 ACETYLCYSTEINE  
     10 ACETYLCYSTEINES  
     7439 ACETYLCYSTEINE  
         (ACETYLCYSTEINE OR ACETYLCYSTEINES)  
 115217 ANTIOXIDANTS  
     1 ANTIOXIDANTSES  
 115218 ANTIOXIDANTS  
     (ANTIOXIDANTS OR ANTIOXIDANTSES)  
     4547 LIPOIC  
 4544597 ACID  
 1617778 ACIDS  
 5053773 ACID  
     (ACID OR ACIDS)  
     4503 LIPOIC ACID  
         (LIPOIC(W)ACID)  
 11529 COFACTORS  
 14650 RIBOFLAVIN  
     67 RIBOFLAVINS  
 14660 RIBOFLAVIN  
     (RIBOFLAVIN OR RIBOFLAVINS)  
     1117 COQ10  
 L5 575 (L3 OR L4) AND (GLUTAMATE EXCITOTOXITY OR BENOQUINONE OR NICOTIN  
     AMIDE OR SPIN TRAPS OR GROWTH FACTOR OR ASPRIN OR NITRIC OXIDE  
     SYNTHASE OR CYCLOOXYGENASE 2 OR ICE OR NEUROIMMUNOPHILIS OR ACET  
     YLCYSTEINE OR ANTIOXIDANTS OR LIPOIC ACID OR COFACTORS OR RIBOFL  
     AVIN OR COQ10)

==> s 15 and parkinson?  
 29704 PARKINSON?

L6


25 L5 AND PARKINSON?

=> d ibib abs hitstr tot

L6 ANSWER 1 OF 25 CAPLUS COPYRIGHT 2008 ACS ON STN  
 ACCESSION NUMBER: 2008:223578 CAPLUS  
 TITLE: Methods and compositions for the treatment of neurodegenerative disorders such as Huntington's disease  
 INVENTOR(S): Jin, Xiaowei; Wilson, Amy Beth; Staunton, Jane; MacDonald, Douglas  
 PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; Chdi, Inc.  
 SOURCE: PCT Int. Appl., 127pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008021210	A2	20080221	WO 2007-US17751	20070810
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM US 2008044390 A1 20080221 US 2007-891552 20070810				
PRIORITY APPLN. INFO.: US 2006-837448P P 20060811 US 2007-898479P P 20070131 US 2007-925777P P 20070423 US 2007-958832P P 20070709				
AB	The present invention features compns., kits, and methods for treating, preventing, and ameliorating neurodegenerative disorders, e.g., Huntington's disease (HD). Screening methods for identifying candidate compds. that treat, prevent, or ameliorate neurodegenerative disorders, e.g., HD, are provided. Thus, N-terminal fragment of Htt has been shown to form protein aggregates in the nucleus, cytoplasm and processes of neurons in human HD patients and in HD animal models, as well as in many cellular models. Because of their similarities to neurons, rat pheochromocytoma PC12 cells have provided a useful model for studying neuronal cell biol.; in addition, PC12 cells are readily transfected, selected and cloned. In order to perform screening according to a method of the present invention, PC12 cells were obtained that stably incorporated a plasmid that inducibly expresses a toxic expanded polyglutamine (103 glutamine) form of exon 1 of Htt, fused to the marker EGFP. Using the engineered PC12/HttN90Q103 cell line, a high throughput assay to screen small molcs. for their ability to prevent mutant Htt exon 1-induced cell death was developed and optimized.			
IT	57-00-1, Creatine RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (methods and compns. for treatment of neurodegenerative disorders such as Huntington's disease)			
RN	57-00-1 CAPLUS			
CN	Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)			





L6 ANSWER 2 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2008:10315 CAPLUS  
 DOCUMENT NUMBER: 148:93258  
 TITLE: Creatine-ligand compounds for treatment of neurological disorders  
 INVENTOR(S): Nivaggioli, Belinda Tsao  
 PATENT ASSIGNEE(S): Avicena Froup, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 16pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2008003208	A1	20080103	US 2007-803008	20070511
PRIORITY APPLN. INFO.:			US 2006-799744P	P 20060511
			US 2007-922147P	P 20070406

AB The present invention provides methods of treating creatine responsive states, such as a neurol. disorder (i.e., Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis and creatine transporter defect) or a skin disorder, by administering a creatine-ligand compound, alone or in combination with an anti-inflammatory compound, to a subject. An example showed the effect of creatine ascorbate on Huntington's disease in 64 subjects.

IT 57-00-1, Creatine 57-00-1D, Creatine, ligands  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (creatine ligand compds. for treatment of neurol. disorders)


RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)




RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



L6 ANSWER 3 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1447899 CAPLUS  
 DOCUMENT NUMBER: 148:45871  
 TITLE: Methods for treating a neurological disorder with creatine monohydrate  
 INVENTOR(S): Nivaggioli, Belinda Tsao  
 PATENT ASSIGNEE(S): Avicena Group, Inc., USA  
 SOURCE: U.S. Pat. Appl. Publ., 16pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007292403	A1	20071220	US 2007-803141	20070511
WO 2007133673	A3	20080117	WO 2007-US11384	20070511
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AP, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, EA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, EP, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, OA, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2006-799743P	P 20060511
			US 2007-922146P	P 20070406
AB	The invention provides methods for treating neurol. disorders, e.g. Huntington's disease, Parkinson's disease and amyotrophic lateral sclerosis, by administering creatine monohydrate and dextrose, alone or in combination with an antiinflammatory compound, to a subject.			
IT	57-00-1, Creatine RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (creatine monohydrate for treatment of neurol. disorders, and combinations wit other agents)			
RN	57-00-1 CAPLUS			
CN	Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)			



L6 ANSWER 4 OF 25 CAPLUS COPYRIGHT 2008 ACS ON STN  
 ACCESSION NUMBER: 2007:1345690 CAPLUS  
 DOCUMENT NUMBER: 147:548116  
 TITLE: Esterified saccharides in treatment of metabolic disorders  
 INVENTOR(S): Henderson, Samuel T.; Orndorff, Steve; Melvin, Lawrence S.  
 PATENT ASSIGNEE(S): Accera Inc., USA  
 SOURCE: PCT Int. Appl., 44pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004077938	A2	20040916	WO 2004-US7191	20040308
WO 2004077938	A3	20050609		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2517929	A1	20040916	CA 2004-2517929	20040308
EP 1605950	A2	20051221	EP 2004-718572	20040308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1756554	A	20060405	CN 2004-80006113	20040308
JP 2006519843	T	20060831	JP 2006-507004	20040308
US 2006189545	A1	20060824	US 2005-546976	20050825
PRIORITY APPLN. INFO.:				
			US 2003-452855P	P 20030306
			WO 2004-US7191	W 20040308


OTHER SOURCE(S): MARPAT 147:548116

AB Methods and compns. for treating or preventing, the occurrence of senile dementia of the Alzheimer's (ALS) type, or other conditions arising from reduced neuronal metabolism and leading to a lower cognitive function are described. In a preferred embodiment the administration of novel esterified saccharide compds. to the patient at a level to produce an improvement in cognitive ability. Use of these compds. will result in hyperketonemia which will provide increased neuronal metabolism for diseases associated with reduced neuronal metabolism such as ALS, Parkinson's disease and Huntington's disease. An esterified saccharide can be combined with compds. that increase the rates of fatty acid utilization such as L-carnitine and its derivs.

IT 57-00-1  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (esterified saccharides in treatment of metabolic disorders)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)





L6 ANSWER 5 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:1224391 CAPLUS  
 DOCUMENT NUMBER: 147:547871  
 TITLE: Mitochondrial nutrients for preventing and improving parkinson's disease  
 INVENTOR(S): Liu, Jiankang; Gao, Hongxiang; Zhang, Hongyu  
 PATENT ASSIGNEE(S): Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Peop. Rep. China  
 SOURCE: Faming Zhuanli Shengqing Gongkai Shuomingshu, 60pp.  
 CODEN: CNXXEV  
 DOCUMENT TYPE: Patent  
 LANGUAGE: Chinese  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CN 101057857	A	20071024	CN 2006-10025907	20060421
PRIORITY APPLN. INFO.:			CN 2006-10025907	20060421

AB The invention provides a medical formulation for preventing and improving Parkinson's disease. The formulation is composed of two or more of following mitochondrial nutrients: R-thioctic acid (R-lipoic acid), acetyl carnitine, vitamin B5, vitamin B6, vitamin B11, vitamin B12, coenzyme Q10, thiamine, lactoflavin, nicotinic acid, biotin, or creatine. The invention relates to the application of the medical composition for prevention, treatment or improvement of Parkinson's disease.


IT 57-00-1, Creatine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (mitochondrial nutrients for preventing and improving parkinson's disease)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



L6 ANSWER 6 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:594210 CAPLUS  
 DOCUMENT NUMBER: 147:132606  
 TITLE: Drug trials in animal models of Parkinson's disease  
 AUTHOR(S): Sa, Daniel S.; Beal, M. Flint  
 CORPORATE SOURCE: Department of Neurology and Neuroscience, Weill Medical College of Cornell University and New York Presbyterian Hospital, New York, NY, USA  
 SOURCE: Neurological Disease and Therapy (2007), 83(Parkinson's Disease), 367-378  
 CODEN: NDTHEE; ISSN: 1058-7535  
 PUBLISHER: Informa Healthcare USA, Inc.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review on recent drug trials in animal models that either aid in understanding neurodegenerative pathways or provide potential therapeutic targets to protect or restore dying neurons, as well as drugs that potentially address other biol. processes in Parkinson's disease besides dopaminergic deficits or provide addnl. symptomatic benefit. Coenzyme Q10, creatine, glial cell line-derived nerve growth factor, minocycline, immunophilin ligands, sonic hedgehog agonists, mixed lineage kinase inhibitor, and opioid receptors are among the drugs discussed.  
 IT 57-00-1, Creatine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (drug trials in animal models of Parkinson's disease)  
 RN 57-00-1 CAPLUS  
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 77 THERE ARE 77 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 7 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:564807 CAPLUS  
 DOCUMENT NUMBER: 146:528329  
 TITLE: Comprehensive nutraceutical agent for  
 treatment/prevention of Parkinson's disease  
 INVENTOR(S): Mazzio, Elizabeth  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 31pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007116779	A1	20070524	US 2006-438746	20060522
PRIORITY APPLN. INFO.:			US 2005-739980P	P 20051123

AB This invention discloses a comprehensive nutraceutical designed to antagonize major mitigating factors specific to the degenerative process that occurs in Parkinson's disease (PD). The formulation is comprised of pyruvate, succinate and/or oxaloacetate further combined with specific macro/micronutrients, trace elements, amino acids, flavonoids and concentrated plant sources. The formula is based on means to attenuate the loss of ATP/toxicity by PD model toxins: 1-methyl-4-phenylpyridinium and rotenone, scavenge hydrogen peroxide/O<sub>2</sub>, augment antioxidant enzymes, prevent dopamine oxidation to DA-quinone via inhibition of COX, PLA2, LOX, xanthine oxidase, tyrosinase, prevent hyperhomocysteinemia, antagonize PARP-1 apoptosis, increase blood flow, glucose and oxygen delivery to the brain, potentiate mitochondrial function, antagonize glia iNOS and MAO or its products, chelate redox-active iron, inhibit hemeoxygenase-1, inhibit alpha-synuclein aggregation, augment ATP storage, mediate antiinflammatory effects via inhibition. of PDE, MAPK p38/c-Jun NH2-terminal kinase/PGE2, antagonize excitotoxicity and downregulate N-methyltransferase, all of which contribute toward PD pathol.

IT 57-00-1, Creatine  
 RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (comprehensive nutraceutical agent for treatment/prevention of Parkinson's disease)

RN 57-00-1 CAPLUS  
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)





L6 ANSWER 8 OF 25 CAPLUS COPYRIGHT 2008 ACS ON STN

ACCESSION NUMBER: 2007:438644 CAPLUS

DOCUMENT NUMBER: 146:437563

TITLE: Methods for rejuvenating somatic cells in vitro and in vivo to become pluripotent or multipotent embryonic stem or stem-like cells for replacing damaged tissues or organs

INVENTOR(S): Hu, Jifan

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 35pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
------------	------	------	-----------------	------

US 2007087437	A1	20070419	US 2006-358465	20060221
---------------	----	----------	----------------	----------

WO 2007047766	A2	20070426	WO 2006-US40723	20061016
---------------	----	----------	-----------------	----------

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2005-726915P P 20051014

US 2006-358465 A 20060221

AB The present invention provides methods for rejuvenating cells, tissues and the whole body. In particular, it provides methods for rejuvenating somatic cells in vitro and in vivo to become pluripotent or multipotent embryonic stem or stem-like cells for replacing damaged or aging tissues or organs and in treatment of diseases such as cancer, leukemia, lymphoma, hematopoietic disorders, CNS trauma, stroke, Alzheimer's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis. Also provided are rejuvenating buffers and agents as well as kits for rejuvenating cells and methods for dedifferentiating somatic cells and differentiating the cells into other cell types. A major advantage of this invention is that it rejuvenates cells or tissues from the patient who will receive the rejuvenated cells. With such autologous cells and tissues, there is no risk of developing graft-vs.-host rejection. Cells to be rejuvenated may be collected from a variety of sources, including skin, blood or bone marrow.


IT 67-07-2, Phosphocreatine

RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)

(rejuvenation solution comprising; methods for rejuvenating somatic cells in vitro and in vivo to become pluripotent or multipotent embryonic stem or stem-like cells for replacing damaged tissues or organs)


RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (CA INDEX NAME)



L6 ANSWER 9 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2007:13634 CAPLUS  
 DOCUMENT NUMBER: 146:75343  
 TITLE: Method to reduce oxidative damage and improve  
 mitochondrial efficiency  
 INVENTOR(S): Henderson, Samuel T.  
 PATENT ASSIGNEE(S): Accera, Inc., USA  
 SOURCE: PCT Int. Appl., 37pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007001883	A2	20070104	WO 2006-US23342	20060615
WO 2007001883	A3	20070531		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA US 2007135376 A1 20070614 US 2006-424429 20060615 PRIORITY APPLN. INFO.: US 2005-692328P P 20050620 AB Methods for the reduction of mitochondrial oxidative damage and improved mitochondrial efficiency in an animal by administration of medium chain triglycerides or prodrug of medium chain triglycerides to the animal are provided. IT 57-00-1, Creatine RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (method to reduce oxidative damage and improve mitochondrial efficiency) RN 57-00-1 CAPLUS CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)				



L6 ANSWER 10 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1204406 CAPLUS

DOCUMENT NUMBER: 145:495647

TITLE: A combination of mitochondrial nutrients for relieving stress and preventing and improving stress-related disorders

INVENTOR(S): Liu, Jiankang

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 15pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006257502	A1	20061116	US 2005-908425	20050511
PRIORITY APPLN. INFO.:			US 2005-908425	20050511

AB A dietary supplement of mitochondrial nutrients is designed for relieving stress and preventing and improving stress-related disorders, such as chronic fatigue syndrome, diabetes, age-associated cognitive dysfunction and diseases (Parkinson's and Alzheimer's disease). The supplement composition has the following nutrients: B vitamins (cyanocobalamin 2-1000 µg, thiamin 1-1000 mg, niacin 15-2000 mg, pyridoxine 1-1000 mg, pantothenate 5-150 mg, and folic acid 400-40,000 µg), α-tocopherol 10-800 mg, ascorbic acid 50-10,000 mg, calcium 20-2000 mg, vitamin A 200-10,000 µg, α-lipoic acid 100-1000 mg, N-acetyl-cysteine 100-3000 mg, L-carnosine 100-9000 mg, tyrosine 100-9000 mg, vanillin 10-100 mg, phosphatidylserine 10-800 mg, resveratrol 10-50 mg, dehydroepiandrosterone 1-50 mg, and melatonin 0.1-3 mg, all of which have been individually used exptl. or clin. for relieving stress, preventing and treating age- and stress-related disorders and diseases but no combination of these compds. has been used. Many embodiments also contain at least one adjunct ingredient such as coenzyme Q 10-200 mg, acetyl-L-carnitine 100-2000 mg, choline 50-1000 mg, and creatine 100-2000 mg.

IT 57-00-1, Creatine  
RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination of natural mitochondrial cofactors and nutrients for relieving stress and preventing and improving stress-related disorders)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



L6 ANSWER 11 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:437475 CAPLUS

DOCUMENT NUMBER: 144:460856

TITLE: Methods and compositions using a bile acid and a carbohydrate for reducing neurodegeneration in amyotrophic lateral sclerosis or other neurodegenerative disease

INVENTOR(S): Yoo, Seo Hong

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006050165	AZ	20060511	WO 2005-US39089	20051031
WO 2006050165	A3	20060706		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005302452	A1	20060511	AU 2005-302452	20051031
CA 2585471	A1	20060511	CA 2005-2585471	20051031
US 2006142241	A1	20060629	US 2005-263087	20051031
EP 1814558	A2	20070808	EP 2005-820886	20051031
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101048164	A	20071003	CN 2005-80037307	20051031
KR 2007089926	A	20070904	KR 2007-712360	20070531
IN 2007KN01990	A	20070810	IN 2007-KN1990	20070604
PRIORITY APPLN. INFO.:				
			US 2004-624100P	P 20041101
			US 2004-628421P	P 20041116
			WO 2005-US39089	W 20051031

AB The invention discloses clear aqueous solns. of one or more bile acids and either an aqueous soluble starch conversion product or a non-starch polysaccharide. The solns. may be administered to a subject in conjunction with a pharmaceutical compound having a therapeutic effect in subjects with a neurodegenerative disease and/or a motor neuron disease. In some embodiments, the disease is amyotrophic lateral sclerosis.


IT 57-00-1, Creatine

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(bile acid and carbohydrate for reducing neurodegeneration in amyotrophic lateral sclerosis or other neurodegenerative disease)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



L6 ANSWER 12 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:216951 CAPLUS

DOCUMENT NUMBER: 144:267302

TITLE: Use of methyl pyruvate or methyl pyruvic acid for the treatment of diseases of the nervous system and for protecting a human central nervous system against neuronal degeneration caused by defective intracellular energy production.

INVENTOR(S): Antosh, Stanley Charles; Meduri, Anthony J.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 10 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2006052448	A1	20060309	US 2004-711255	20040904
WO 2006028948	A2	20060316	WO 2005-US31249	20050831
WO 2006028948	A3	20070329		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1796460	A2	20070620	EP 2005-793039	20050831
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				

PRIORITY APPLN. INFO.: US 2004-711255 A 20040904  
WO 2005-US31249 W 20050831

AB The present invention relates to the use of Me pyruvic acid (a Me ester of pyruvic acid) and/or Me pyruvate (Me pyruvate is the ionized form of Me pyruvic acid) for the purpose of treating diseases of the nervous system and/or to prevent against neuronal degeneration due to defective intracellular energy production. Me pyruvate compds. can be used as therapeutically effective agents against a variety of diseases of the nervous system such as diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotrophic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination, demyelination disorders, or cellular disorders which interfere with the energy metabolism of neurons and mitochondrial diseases. Use of Me pyruvate and/or Me pyruvic acid can be effective when administered orally or infused on either a chronic and/or acute basis. Treatment can be effective even when administered after the onset of an ischemic event that triggers neurodegeneration. In the following text, the terms "methyl pyruvate, Me pyruvate compds., Me pyruvic acid" are used interchangeably.

IT 57-00-1, Creatine 57-00-1D, Creatine, analogs

67-07-2, Creatine phosphate 67-07-2D,

N-Phosphocreatine, analogs


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(use of Me pyruvate or Me pyruvic acid for treatment of diseases of nervous system and neuronal degeneration caused by defective intracellular energy production and combination with other agents)


RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)




RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)




RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (CA INDEX NAME)



RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (CA INDEX NAME)





L6 ANSWER 13 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:147331 CAPLUS

DOCUMENT NUMBER: 144:219283

TITLE: Physiologically acceptable composition containing  
alpha-lipoic acid, creatine, and a  
phosphatide

INVENTOR(S): Schuhbauer, Hans; Jaeger, Ralf; Purpura, Martin

PATENT ASSIGNEE(S): Bioghurt Biogarde GmbH & Co. KG, Germany

SOURCE: PCT Int. Appl., 26 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006015774	A1	20060216	WO 2005-EP8375	20050802
<p>W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW</p> <p>RW: AI, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM</p>				
DE 102004038155	A1	20060316	DE 2004-102004038155	20040806
<p>PRIORITY APPL. INFO.: DE 2004-102004038155A 20040806</p>				
<p>AB Disclosed is a novel physiol. acceptable composition substantially containing α- lipoic acid, creatine and a phosphatide and/or one of the suitable derivs. thereof. Said composition preferably contains 0.01% to 80% by weight of the lipoic acid component, 1.0% to 99.9% of the creatine component, and 0.01% to 80% by weight of the phosphatide component and is used mainly for slowing down degenerative and particularly progressive modifications of the brain. Forms of administration such as food supplements, food, beverages, medicaments, cosmetics are particularly suitable. In general, the disclosed composition is used in individual doses ranging between 10 mg and 10 g. The inventive combination makes it possible to obtain results which additively exceed the effects of the individual compds. while representing cases of application that were unknown for the individual compds. Thus a gelatin capsule contained (mg): (±)-α- lipoic acid 60; creatine monohydrate 400; phosphatidylserine 40.</p>				
IT	<p>57-00-1, Creatine 67-07-2, Creatine phosphate RL: FFD (Food or feed use); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (physiol. acceptable composition containing α- lipoic acid, creatine, and phosphatide)</p>			
RN	57-00-1 CAPLUS			
CN	Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)			



RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 14 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1310905 CAPLUS  
 DOCUMENT NUMBER: 144:45513  
 TITLE: Composition comprising Xanthoceras sorbifolia  
 extracts, compounds isolated from same, methods for  
 preparing same, and uses thereof  
 INVENTOR(S): Chan, Pui-Kwong; Mak, May Sung; Wang, Yun  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 194 pp., Cont.-in-part of U.S.  
 Ser. No. 906,303.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 12  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005276872	A1	20051215	US 2005-117760	20050427
US 2003091669	A1	20030515	US 2001-944805	20010831
US 6616943	B2	20030909		
WO 2003017919	A2	20030306	WO 2002-IB4750	20020828
WO 2003017919	A3	20040722		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2004146591	A1	20040729	US 2003-471384	20030904
US 7189420	B2	20070313		
WO 2005037200	A2	20050428	WO 2004-US33359	20041008
WO 2005037200	A3	20050616		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
WO 2005063273	A1	20050714	WO 2004-US43465	20041223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2005220910	A1	20051006	US 2005-906303	20050214
AU 2005282437	A1	20060316	AU 2005-282437	20050907

CA 2579231	A1	20060316	CA 2005-2579231	20050907
WO 2006029221	A2	20060316	WO 2005-US31900	20050907
WO 2006029221	A3	20070412		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
EP 1811840	A2	20070801	EP 2005-810263	20050907
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
US 2006111310	A1	20060525	US 2005-267523	20051104
US 2006122129	A1	20060608	US 2005-289142	20051128
WO 2006116656	A2	20061102	WO 2006-US16158	20060427
WO 2006116656	A3	20070215		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 2006263458	A1	20061123	US 2006-412659	20060427
EP 1876896	A2	20080116	EP 2006-751723	20060427
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR			
KR 2007113185	A	20071128	KR 2007-707902	20070406
CN 10123880	A	20080213	CN 2005-80037524	20070429
PRIORITY APPLN. INFO.:			US 2001-944805	A2 20010831
			WO 2002-IB4750	W 20020828
			US 2003-471384	A2 20030904
			US 2003-509851P	P 20031009
			US 2003-532101P	P 20031223
			US 2004-607858P	P 20040907
			US 2004-613811P	P 20040927
			US 2004-617379P	P 20041008
			WO 2004-US33359	A2 20041008
			WO 2004-US43465	A2 20041223
			US 2005-906303	A2 20050214
			US 2005-117760	A 20050427
			US 2005-675282P	P 20050427
			US 2005-675284P	P 20050427
			US 2005-131551	A 20050517
			WO 2005-US31900	W 20050907
			US 2005-267523	A2 20051104
			US 2005-289142	A 20051128
			WO 2006-US16158	W 20060427

OTHER SOURCE(S): MARPAT 144:45513

AB This invention provides compns., methods and process of producing exts.

and pure compds. from *Xanthoceras sorbifolia*. The extract comprises saponins and other constituents including alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, tannins, acid, flavonoids and others. The composition can be used for treating cancer and other conditions, such as arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, kidney disorder, and impotence; for improving cerebral functions; or for curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's, cerebral dysfunctions, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, headache, dizziness, kidney disorder. This invention provides compds. of oleanene triterpenoidal saponin in nature with the characteristics that at least one angeloyl group attaches to Carbon 21 or/and 22, or/and linked to the sugar. The compds. of the present invention have various pharmaceutical and therapeutic applications.

IT 57-00-1, Creatine


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(*Xanthoceras sorbifolia* extract composition, isolated compds., preparation methods,

and therapeutic use)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



L6 ANSWER 15 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:369224 CAPLUS

DOCUMENT NUMBER: 142:423889

TITLE: Composition comprising Xanthoceras sorbifolia extracts, isolated compounds, preparation methods, and therapeutic use

INVENTOR(S): Chan, Pui-Kwong; Mak, May Sung; Wang, Yun

PATENT ASSIGNEE(S): Pacific Arrow Limited, Peop. Rep. China

SOURCE: PCT Int. Appl., 237 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005037200	A2	20050428	WO 2004-US33359	20041008
WO 2005037200	A3	20050616		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2004281707	A1	20050428	AU 2004-281707	20041008
CA 2541425	A1	20050428	CA 2004-2541425	20041008
EP 1670491	A2	20060621	EP 2004-809909	20041008
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK			
JP 2007508317	T	20070405	JP 2006-534419	20041008
WO 2005063273	A1	20050714	WO 2004-US43465	20041223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1708724	A1	20061011	EP 2004-815530	20041223
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS			
CN 1972702	A	20070530	CN 2004-80038698	20041223
JP 2007523058	T	20070816	JP 2006-547422	20041223
US 2005220910	A1	20051006	US 2005-906303	20050214
US 2005245470	A1	20051103	US 2005-117745	20050427
US 2005276872	A1	20051215	US 2005-117760	20050427
US 2005277601	A1	20051215	US 2005-131551	20050517
US 7262285	B2	20070828		
AU 2005282437	A1	20060316	AU 2005-282437	20050907
CA 2579231	A1	20060316	CA 2005-2579231	20050907
WO 2006029221	A2	20060316	WO 2005-US31900	20050907
WO 2006029221	A3	20070412		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

EP 1811840 A2 20070801 EP 2005-810263 20050907

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU

US 2006111310 A1 20060525 US 2005-267523 20051104

US 2006122129 A1 20060608 US 2005-289142 20051128

US 2006263458 A1 20061123 US 2006-412659 20060427

US 2007161580 A1 20070712 US 2007-683198 20070307

KR 2007113185 A 20071128 KR 2007-707902 20070406

CN 101123880 A 20080213 CN 2005-80037524 20070429

PRIORITY APPLN. INFO.:

US 2003-509851P P 20031009

US 2003-532101P P 20031223

US 2001-944805 A2 20010831

WO 2002-1B4750 W 20020828

US 2003-471384 A2 20030904

US 2004-607858P P 20040907

US 2004-613811P P 20040927

US 2004-617379P P 20041008

WO 2004-US33359 W 20041008

WO 2004-US43465 W 20041223

US 2005-906303 A2 20050214

US 2005-117745 A2 20050427

US 2005-117760 A 20050427

US 2005-675282P P 20050427

US 2005-675284P P 20050427

US 2005-131551 A 20050517

WO 2005-US31900 W 20050907

US 2005-267523 A2 20051104

US 2005-289142 A2 20051128

US 2006-795417P P 20060427

WO 2006-US16158 A 20060427

US 2006-841727P P 20060901

US 2007-890380P P 20070216

OTHER SOURCE(S): MARPAT 142:423889

AB The invention provides compns., methods and process of producing exts. from *Xanthoceras sorbifolia*. The extract comprises alkaloids, coumarins, saccharides, proteins, polysaccharides, glycosides, saponins, tannins, acid, flavonoids and others. The composition can be used for anticancer, preventing cerebral aging, improving memory, improving cerebral functions and curing enuresis, frequent micturition, urinary incontinence, dementia, weak intelligence and Alzheimer's disease, autism, brain trauma, Parkinson's disease and other diseases caused by cerebral dysfunction, and treating arthritis, rheumatism, poor circulation, arteriosclerosis, Raynaud's syndrome, angina pectoris, cardiac disorder, coronary heart disease, headache, dizziness, kidney disorder and treating impotence and premature ejaculation. The invention provides compds. comprise a sugar, terpenes, e.g. sapogenin, and a side chains at carbon 21 and 22, e.g. angeloyl groups. The compds. of the invention have various pharmaceutical and therapeutic applications.

IT 57-00-1, Creatine


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(Xanthoceras sorbifolia extract composition, isolated compds., preparation  
methods,

and therapeutic use)


RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)






L6 ANSWER 16 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:983902 CAPLUS  
 DOCUMENT NUMBER: 142:425007  
 TITLE: Caenorhabditis elegans MPP model of Parkinson  
 's disease for high-throughput drug screenings  
 AUTHOR(S): Braungart, Evelyn; Gerlach, Manfred; Riederer, Peter;  
 Baumeister, Ralf; Hoener, Marius C.  
 CORPORATE SOURCE: Pieris Proteolab AG, Freising-Weißenstephan, Germany  
 SOURCE: Neurodegenerative Diseases (2004), 1(4-5), 175-183  
 CODEN: NDEIA6; ISSN: 1660-2854  
 PUBLISHER: S. Karger AG  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB The neurotoxin MPTP and its active metabolite MPP+ cause Parkinson  
 's disease (PD)-like symptoms in vertebrates by selectively destroying  
 dopaminergic neurons in the substantia nigra. MPTP/MPP+ models have been  
 established in rodents to screen for pharmacol. active compds. In addition  
 to being costly and time consuming, these animal models are not suitable  
 for large scale testings using compound libraries. The authors present a  
 novel MPP+-based model for high-throughput screenings using the nematode  
 Caenorhabditis elegans. Incubation of C. elegans with MPTP or its active  
 metabolite MPP+ resulted in strong symptomatic defects including reduced  
 mobility and increased lethality, and is correlated with a specific  
 degeneration of the dopaminergic neurons. The phenotypic consequences of  
 MPTP/MPP+ treatments were recorded using automated hardware and software  
 for quantification. Incubation of C. elegans with a variety of pharmacol.  
 active components used in PD treatment reduced the MPP+-induced defects.  
 These data suggest that the C. elegans MPTP/MPP+ model can be used for the  
 quant. evaluation of anti-PD drugs.  
 IT 57-00-1, Creatine  
 RL: BSU (Biological study, unclassified); THU (Therapeutic use); BIOL  
 (Biological study); USES (Uses)  
 (Caenorhabditis elegans MPP model of Parkinson's disease for  
 high-throughput drug screenings)  
 RN 57-00-1 CAPLUS  
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS  
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 17 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2004:934313 CAPLUS  
 DOCUMENT NUMBER: 141:400910  
 TITLE: Medical composition for balancing bodily processes  
 INVENTOR(S): Bland, Jeffrey S.; Liska, Deann J.; Krumhar, Kim  
 Carleton; Tripp, Matthew L.; Darland, Gary K.; Lerman,  
 Robert H.; Lukaczer, Daniel O.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 40 pp., Cont.-in-part of U.S.  
 Ser. No. 352,388.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 3  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004220118	A1	20041104	US 2003-735526	20031211
US 2002192310	A1	20021219	US 2002-56858	20020123
US 2003190381	A1	20031009	US 2003-352388	20030127
US 2007059378	A1	20070315	US 2006-598429	20061113
US 2007087063	A1	20070419	US 2006-638746	20061214
PRIORITY APPLN. INFO.:			US 2001-265908P	P 20010202
			US 2002-56858	A2 20020123
			US 2002-352016P	P 20020125
			US 2002-432689P	P 20021211
			US 2003-352388	A2 20030127
			US 2003-735526	A3 20031211
AB			Medical compns. and methods using same to nutritionally support balance of bodily processes are disclosed. A medical composition to nutritionally support balance of bodily processes involving S-adenosylmethionine is disclosed. A medical composition in the form of tablets for nutritional support of women with symptoms associated with hormone cycles contained vitamin A 2500 IU, vitamin D 200 IU, vitamin E 200 IU, vitamin K 40 mcg, vitamin B6 50 mg, vitamin B12 30 mcg, folic acid 800 mcg, isoflavones 100 mg, curcumin 200 mg, trimethylglycine 200 mg, resveretrol 2 mg, rosemary extract 200 mg, and chrysin 100 mg. The effects of the tablets was clin. studied in women.	
IT			57-00-1, Creatine	
RL			BSU (Biological study, unclassified); BIOL (Biological study) (medical composition for balancing bodily processes)	
RN			57-00-1 CAPLUS	
CN			Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)	



L6 ANSWER 18 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:949255 CAPLUS  
 DOCUMENT NUMBER: 140:210533  
 TITLE: Additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease  
 AUTHOR(S): Klivenyi, Peter; Gardian, Gabrielle; Calingasan, Noel Y.; Yang, Lichuan; Beal, M. Flint  
 CORPORATE SOURCE: Department of Neurology and Neuroscience, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, 10021, USA  
 SOURCE: Journal of Molecular Neuroscience (2003), 21(3), 191-198  
 CODEN: JMNEES; ISSN: 0895-8696  
 PUBLISHER: Humana Press Inc.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English  
 AB There is evidence that both inflammatory mechanisms and mitochondrial dysfunction contribute to Parkinson's disease (PD) pathogenesis. We investigated whether the cyclooxygenase 2 (COX-2) inhibitor rofecoxib either alone or in combination with creatine could exert neuroprotective effects in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of PD in mice. Both rofecoxib and creatine administered alone protected against striatal dopamine depletions and loss of substantia nigra tyrosine hydroxylase immunoreactive neurons. Administration of rofecoxib with creatine produced significant additive neuroprotective effects against dopamine depletions. These results suggest that a combination of a COX-2 inhibitor with creatine might be a useful neuroprotective strategy for PD.  
 IT 57-00-1, Creatine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (additive neuroprotective effects of creatine and a cyclooxygenase 2 inhibitor against dopamine depletion in mouse model of Parkinson's disease)  
 RN 57-00-1 CAPLUS  
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 19 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:855794 CAPLUS

DOCUMENT NUMBER: 139:345938

TITLE: Combination therapy including cyclooxygenase  
2 (COX2) inhibitor(s) for the treatment of  
Parkinson's disease

INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz,  
Timothy J.

PATENT ASSIGNEE(S): Pharmacia Corporation, USA

SOURCE: PCT Int. Appl., 266 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088958	A2	20031030	WO 2003-US11269	20030414
WO 2003088958	A3	20040819		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2481934	A1	20031030	CA 2003-2481934	20030414
AU 2003223579	A1	20031103	AU 2003-223579	20030414
US 2004034083	A1	20040219	US 2003-413348	20030414
EP 1494664	A2	20050112	EP 2003-719717	20030414
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2003009259	A	20050209	BR 2003-9259	20030414
JP 2005528403	T	20050922	JP 2003-585710	20030414
MX 2004PA09352	A	20050125	MX 2004-PA9352	20040924
PRIORITY APPLN. INFO.:			US 2002-373311P	P 20020418
			WO 2003-US11269	W 20030414


OTHER SOURCE(S): MARPAT 139:345938

AB The invention discloses a method for treating, preventing, or inhibiting Parkinson's disease (PD) in a subject in need of such treatment, inhibition, or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes a PD treatment-, inhibition- or prevention-effective amount


IT 57-00-1, Creatine  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(combination therapy including cyclooxygenase 2 inhibitor for treatment of Parkinson's disease)

RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



L6 ANSWER 20 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:765720 CAPLUS  
 DOCUMENT NUMBER: 140:174175  
 TITLE: Targeting cellular energy production in neurological disorders  
 AUTHOR(S): Baker, Steven K.; Tarnopolsky, Mark A.  
 CORPORATE SOURCE: Department of Medicine, Neurology and Rehabilitation, McMaster University, Hamilton, ON, L8N 3Z5, Can.  
 SOURCE: Expert Opinion on Investigational Drugs (2003), 12(10), 1655-1679  
 CODEN: EOIDER; ISSN: 1354-3784  
 PUBLISHER: Ashley Publications Ltd.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review. The concepts of energy dysregulation and oxidative stress and their complicated interdependence have rapidly evolved to assume primary importance in understanding the pathophysiol. of numerous neurol. disorders. Therefore, neuroprotective strategies addressing specific bioenergetic defects hold particular promise in the treatment of these conditions (i.e., amyotrophic lateral sclerosis, Huntington's disease, Parkinson's disease, Friedreich's ataxia, mitochondrial cytopathies and other neuromuscular diseases), all of which, to some extent, share the final common pathway' leading to cell death through either necrosis or apoptosis. Compds. such as creatine monohydrate and coenzyme Q10 offer substantial neuroprotection against ischemia, trauma, oxidative damage and neurotoxins. Miscellaneous agents, including  $\alpha$ -lipoic acid,  $\beta$ -OH- $\beta$ -methylbutyrate, riboflavin and nicotinamide, have also been shown to improve various metabolic parameters in brain and/or muscle. This review will highlight the biol. function of each of the above mentioned compds. followed by a discussion of their utility in animal models and human neurol. disease. The balance of this work will be comprised of discussions on the therapeutic applications of creatine and coenzyme Q10.  
 IT 57-00-1, Creatine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (targeting cellular energy production in neurol. disorders)  
 RN 57-00-1 CAPLUS  
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)




REFERENCE COUNT: 330 THERE ARE 330 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


L6 ANSWER 21 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:319452 CAPLUS  
 DOCUMENT NUMBER: 138:314630  
 TITLE: Orthomolecular sulfo-adenosylmethionine derivatives  
 with antioxidant properties  
 INVENTOR(S): Wilburn, Michael D.  
 PATENT ASSIGNEE(S): USA  
 SOURCE: U.S. Pat. Appl. Publ., 17 pp.  
 CODEN: USXXCO  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003078231	A1	20030424	US 2001-886612	20010622
PRIORITY APPLN. INFO.:			US 2001-886612	20010622
OTHER SOURCE(S):	MARPAT	138:314630		

GI




- AB Disclosed are orthomol. sulfo-adenosylmethionine derivative compds., compns., and their uses for effecting a biol. activity in an animal, such as neurochem. activity; liver biol. activity; heart and artery function; cartilage, bone and joint health; stomach and/or intestinal lining resistance to ulceration; immune function; cell membrane integrity; and pain and inflammation. The compds. of the present invention are further useful for preventing or treating diseases or conditions; treating viral infections, infectious diseases, leukemia, and obesity; and reducing the risk of Sudden Infant Death Syndrome in an animal. The compds. of the present invention are I (R1 = H, C1-C10 alkyl, C2-C10 alkenyl or alkynyl, -C(O)R2; R2 = C1-C10 alkyl, C2-C10 alkenyl or alkynyl; Q = -C(NH3)C(O)AX, -C(COOH)NHX; A = O, N; X = a defined reaction product) or pharmaceutically acceptable salt, ester or solvate thereof.  $\alpha$ -(S-adenosylmethionine)-O-tocopherol was prepared from N-Acetyl-S-benzyl-L-homocysteine,  $\alpha$ -tocopherol, and 5'-O-p-Tolylsulfonyl-adenosine.
- IT 57-00-1D, Creatine, reaction products with S-adenosyl-L-methionine derivs. 67-07-2D, Phosphocreatine, reaction products with S-adenosyl-L-methionine derivs.
- RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
- (orthomol. S-adenosyl-L-methionine derivs. with antioxidant properties)
- RN 57-00-1 CAPLUS
- CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)




RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (CA INDEX NAME)





L6 ANSWER 22 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2003:315166 CAPLUS  
 DOCUMENT NUMBER: 139:316285  
 TITLE: Bioenergetic approaches for neuroprotection in Parkinson's disease  
 AUTHOR(S): Beal, M. Flint  
 CORPORATE SOURCE: Department of Neurology and Neuroscience, New York Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA  
 SOURCE: Annals of Neurology (2003), 53(Suppl. 3), S39-S48  
 CODEN: ANNE3; ISSN: 0364-5134  
 PUBLISHER: Wiley-Liss, Inc.  
 DOCUMENT TYPE: Journal; General Review  
 LANGUAGE: English  
 AB A review. There is considerable evidence suggesting that mitochondrial dysfunction and oxidative damage may play a role in the pathogenesis of Parkinson's disease (PD). This possibility has been strengthened by recent studies in animal models, which have shown that a selective inhibitor of complex I of the electron transport gene can produce an animal model that closely mimics both the biochem. and histopathol. findings of PD. Several agents are available that can modulate cellular energy metabolism and that may exert antioxidative effects. There is substantial evidence that mitochondria are a major source of free radicals within the cell. These appear to be produced at both the iron-sulfur clusters of complex I as well as the ubiquinone site. Agents that have shown to be beneficial in animal models of PD include creatine, coenzyme Q10, Ginkgo biloba, nicotinamide, and acetyl-L-carnitine. Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD. Similarly, coenzyme Q10 is also effective in animal models and has shown promising effects both in clin. trials of PD as well as in clin. trials in Huntington's disease and Friedreich's ataxia. Many other agents show good human tolerability. These agents therefore are promising candidates for further study as neuroprotective agents in PD.  
 IT 57-00-1, Creatine  
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (bioenergetic approaches for neuroprotection in Parkinson's disease)  
 RN 57-00-1 CAPLUS  
 CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 101 THERE ARE 101 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 23 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:833099 CAPLUS

DOCUMENT NUMBER: 135:362605

TITLE: Nutritional preparation comprising ribose and folic acid and medical use thereof

INVENTOR(S): Hageman, Robert Johan Joseph; Smeets, Rudolf Leonardus Lodewijk; Verlaan, George

PATENT ASSIGNEE(S): N.V. Nutricia, Neth.

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001085178	A1	20011115	WO 2001-NL349	20010508
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6420342	B1	20020716	US 2000-566381	20000508
EP 1282426	A1	20030212	EP 2001-930315	20010508
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003532679	T	20031105	JP 2001-581831	20010508
US 2002183263	A1	20021205	US 2002-178736	20020625
US 6548483	B2	20030415		
PRIORITY APPLN. INFO.:			US 2000-566381	A 20000508
			WO 2001-NL349	W 20010508
AB	Trauma, surgery, inflammation, subfertility, lactation problems, gut disorders, infant nutrition, cancer, arthritis and other joint problems, vascular problems and cardio- or cerebrovascular problems, ischemia, aging, impaired immune function, burns, sepsis, malnutrition, problems with liver or kidneys, malaria, cystic fibrosis, migraine, neuropathology, respiratory infections, improvement of sports results, muscle soreness, drug intoxication and pain can be treated with a nutritional composition containing effective amts. of ribose and folic acid, optionally combined with other components such as niacin, histidine, glutamine, orotate, vitamin B6 and other components.			
IT	57-00-1, Creatine			
	RL: FFD (Food or feed use); MOA (Modifier or additive use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(nutritional preparation comprising ribose and folic acid and medical use)			
RN	57-00-1 CAPLUS			
CN	Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)			



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



L6 ANSWER 24 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:659188 CAPLUS

DOCUMENT NUMBER: 131:281583

TITLE: Compositions containing a combination of a creatine compound and a neuroprotective compound for the treatment of nervous system diseases

INVENTOR(S): Kaddurah-Daouk, Rima; Beal, M. Flint

PATENT ASSIGNEE(S): Avicena Group, Inc., USA; The General Hospital Corporation

SOURCE: PCT Int. Appl., 81 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9951097	A1	19991014	WO 1999-US7340	19990402
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2327095	A1	19991014	CA 1999-2327095	19990402
AU 9933803	A	19991025	AU 1999-33803	19990402
AU 759467	B2	20030417		
EP 1065931	A1	20010110	EP 1999-915245	19990402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002510604	T	20020409	JP 2000-541878	19990402
AU 2003200532	A1	20030417	AU 2003-200532	20030214
US 2006128643	A1	20060615	US 2006-342727	20060130
US 2006128671	A1	20060615	US 2006-343116	20060130
AU 2006202505	A1	20060706	AU 2006-202505	20060613
PRIORITY APPLN. INFO.:			US 1998-80459P	P 19980402
			US 1999-283267	A 19990401
			AU 1999-33803	A3 19990402
			US 1999-285395	B2 19990402
			WO 1999-US7340	W 19990402
			US 2000-687575	A1 20001013
			AU 2003-200532	A3 20030214

OTHER SOURCE(S): MARPAT 131:281583


AB The invention relates to the use of creatine compound and neuroprotective combinations including creatine, creatine phosphate, or analogs of creatine, such as cyclocreatine, for treating diseases of the nervous system. Creatine compds. in combination with neuroprotective agents can be used as therapeutically effective compns. against a variety of diseases of the nervous system, e.g. diabetic and toxic neuropathies, peripheral nervous system diseases, Alzheimer disease, Parkinson's disease, stroke, Huntington's disease, amyotrophic lateral sclerosis, motor neuron disease, traumatic nerve injury, multiple sclerosis, dysmyelination and demyelination disorders, and mitochondrial diseases. The creatine compds. which can be used in the present method include (1) creatine, creatine phosphate and analogs of these compds. which can act as substrates or substrate analogs for creatine kinase; (2) bisubstrate inhibitors of creatine kinase comprising covalently linked structural analogs of ATP and creatine; (3) creatine analogs which can act as reversible or irreversible inhibitors of creatine kinase; and (4) N-phosphorocreatine analogs bearing

nontransferable moieties which mimic the N-phosphoryl group.

IT 57-00-1 57-00-1D, Creatine, analogs 67-07-2,  
Creatine phosphate  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(creatine compound-neuroprotective compound combination for treatment of nervous system disease)


RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)




RN 57-00-1 CAPLUS

CN Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)



RN 67-07-2 CAPLUS

CN Glycine, N-[imino(phosphonoamino)methyl]-N-methyl- (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 25 OF 25 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1999:297312 CAPLUS

DOCUMENT NUMBER: 130:320858

TITLE: Nutritional supplement for cerebral metabolic insufficiencies

INVENTOR(S): Blass, John P.

PATENT ASSIGNEE(S): Cornell Research Foundation, Inc., USA

SOURCE: PCT Int. Appl., 27 pp.

CODEN: PIXXD2


DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921565	A1	19990506	WO 1998-US18120	19980901
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2306875	A1	19990506	CA 1998-2306875	19980901
AU 9892139	A	19990517	AU 1998-92139	19980901
AU 760140	B2	20030508		
EP 1032403	A1	20000906	EP 1998-944644	19980901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001521002	T	20011106	JP 2000-517723	19980901
US 6537969	B1	20030325	US 2000-529091	20001020
US 2003176365	A1	20030918	US 2003-379816	20030304
PRIORITY APPLN. INFO.:				
			US 1997-63165P	P 19971024
			WO 1998-US18120	W 19980901
			US 2000-529091	A1 20001020
AB	The present invention relates to a pharmaceutical composition which includes a sugar and a Krebs cycle intermediate, or salt thereof, or a precursor of a Krebs cycle intermediate. Krebs cycle intermediates include citric acid, aconitic acid, isocitric acid, $\alpha$ -ketoglutaric, succinic acid, fumaric acid, malic acid, and oxaloacetic acid, and mixts. thereof. Precursors of Krebs cycle intermediates are compds. converted by the body to form a Krebs cycle intermediate. The present invention also relates to administration of the pharmaceutical composition to treat an individual for a disorder involving impaired mitochondrial function and to improve cerebral function in an individual having impaired cerebral metabolism			
IT	57-00-1, Creatine			
	RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, nonclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)			
	(as adjuvant; nutritional supplements containing sugars and Krebs cycle intermediates for improving impaired mitochondrial functions)			
RN	57-00-1 CAPLUS			
CN	Glycine, N-(aminoiminomethyl)-N-methyl- (CA INDEX NAME)			



REFERENCE COUNT:

2

THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

190.97

206.40

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-20.00

-20.00

STN INTERNATIONAL LOGOFF AT 19:19:40 ON 13 MAR 2008